
22/08/2025
South Africa could soon have a new tool in its fight against HIV: , a six-monthly injection that has been hailed as a breakthrough in prevention.
If all goes according to plan, rollout could begin as early as March or April 2026, says Hasina Subedar, senior technical advisor for Prevention at the National Department of Health. But this depends on regulatory approval and the cost of the drug.
Studies in South Africa and abroad show lenacapavir is highly effective at preventing HIV. At the International AIDS Conference in Rwanda this year, the World Health Organisation released guidelines on its use.
The drug has already been approved by the U.S. FDA.
But South Africa must wait for a decision from its own regulator, SAHPRA, before the drug can be considered for the essential medicines list. Without that listing, it cannot be procured for public use.
Cost may prove the toughest challenge. Oral PrEP costs just $40 per person per year, but manufacturer Gilead Sciences has reportedly priced lenacapavir at more than $28,000 per person per year. The Global Fund has stepped in to negotiate access for low- and middle-income countries, but details remain unclear.
Find out more in the comments.